Vertaling van "disease and has been used " (Nederlands → Frans) :

Approved in up to six indications worldwide, Reclast/Aclasta provides fracture protection to a broad spectrum of patients ranging from those diagnosed with early bone loss to patients with more severe forms of the disease and has been used in more than one million infusions.
Autorisé pour jusqu’à six indications dans le monde entier, Aclasta/Reclast protège contre les fractures sur toute l’étendue de la maladie allant de la perte osseuse précoce aux formes plus sévères.

Extavia (USD 12 million), for patients with some forms of multiple sclerosis (MS), has been prescribed for use by about 3,000 patients in Europe since the early 2009 launch that marks the entry of Novartis into this disease area.
Extavia (USD 12 millions), pour les malades atteints de certaines formes de sclérose en plaques (SEP), a été prescrit à quelque 3000 malades en Europe depuis son lancement début 2009 qui marque l’entrée de Novartis dans ce domaine thérapeutique.

Reclast/Aclasta (USD 200 million, +105% lc), the first once-yearly infusion therapy for osteoporosis, has been fueled by increasing patient access to infusion centers in the US and Europe as well as a growing list of approved indications for use in a broad range of patients suffering from various types of this debilitating disease.
Aclasta/Reclast (USD 200 millions, +105% en m. l.), premier traitement de l’ostéoporose par perfusion annuelle, a bénéficié de l’accroissement du nombre de centres de perfusion facilitant l’accès aux malades aux Etats-Unis et en Europe ainsi que l’allongement de la liste des indications autorisées pour une utilisation chez de nombreux malades souffrant de différents types de cette maladie invalidante.

This biotechnology eye therapy, which is approved in more than 80 countries for “wet” age-related macular degeneration, has now been used in more than 250,000 patients for this disease, a leading cause of blindness in people over age 50.
Ce traitement oculaire issu des biotechnologies, autorisé dans plus de 80 pays contre la forme exsudative de la dégénérescence maculaire liée à l'âge, cause principale de cécité chez les personnes âgées de plus de 50 ans, a été utilisé chez plus de 250 000 malades.

Zometa (USD 701 million, +10% lc), an intravenous bisphosphonate therapy for patients with cancer that has spread to the bones, has been growing due to improved compliance and use in existing indications.
Zometa (USD 701 millions, +10% en m. l.), bisphosphonate intraveineux contre les métastases osseuses du cancer, a continué de progresser grâce à une amélioration de sa conformité aux indications existantes.

Aclasta/Reclast (USD 254 million), the first once-yearly infusion therapy for various forms of osteoporosis, has now been used in more than 350,000 patients and has experienced consistent growth since its launch to treat postmenopausal osteoporosis in late 2007.
Aclasta/Reclast (USD 254 millions), première injection annuelle pour soigner différentes formes d’ostéoporose, a été utilisé par plus de 350 000 patients et a affiché une croissance notable depuis son lancement, à fin 2007, pour le traitement de l’ostéoporose potsménopausique.

As mentioned in the definition of the terms used, the notion of depressiveness has not been defined in a clear and internationally recognised way. It follows that few studies allow an exact quantification of the concrete realities behind it.
Comme nous l’avons vu dans la définition des termes, le concept de dépressivité n’étant pas défini de façon claire et reconnue internationalement, peu d’études permettent de quantifier exactement les réalités concrètes qu’il recouvre.

For 2007, an analysis has been performed of the number of submitted applications versus the number of MA of medicines for human use granted.
For 2007, an analysis has been performed of the number of submitted applications versus the number of MA of medicines for human use granted.

The latter has been designated as having expertise as an “Official Medicines Control Laboratory”, recognised by the FAMHP and the European Directorate for the Quality of Medicines (EDQM), for the monitoring of immunological products for veterinary use prior to marketing authorisation for the Belgian market.
The latter has been designated as having expertise as an “Official Medicines Control Laboratory”, recognised by the FAMHP and the European Directorate for the Quality of Medicines (EDQM), for the monitoring of immunological products for veterinary use prior to marketing authorisation for the Belgian market.

At our Tongi plant in Bangladesh, streamlined production lines have improved energy efficiency; the use of water pumps, chillers and cooling tower fans has been minimized.
Dans notre usine de Tongi, au Bangladesh, la rationalisation des lignes de production a permis d’améliorer le bilan énergétique global : utilisation plus restreinte des pompes à eau, des ventilateurs et des tours de refroidissement.